APP-FUBINACA

APP-FUBINACA
Legal status
Legal status
Identifiers
IUPAC name
  • N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC24H21FN4O2
Molar mass416.456 g·mol−1
3D model (JSmol)
SMILES
  • O=C(N[C@H](C(N)=O)CC1=CC=CC=C1)C2=NN(CC3=CC=C(F)C=C3)C4=C2C=CC=C4
InChI
  • InChI=1S/C24H21FN4O2/c25-18-12-10-17(11-13-18)15-29-21-9-5-4-8-19(21)22(28-29)24(31)27-20(23(26)30)14-16-6-2-1-3-7-16/h1-13,20H,14-15H2,(H2,26,30)(H,27,31)/t20-/m0/s1
  • Key:TZXBEYFALIFOAG-FQEVSTJZSA-N

APP-FUBINACA is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] Pharmacological testing showed APP-FUBINACA to have only moderate affinity for the CB1 receptor, with a Ki of 708 nM, while its EC50 was not tested.[2] It contains a phenylalanine amino acid residue in its structure.

Legality

Sweden's public health agency suggested to classify APP-FUBINACA as hazardous substance on March 24, 2015.[3]

See also

References

  1. ↑ "APP-FUBINACA". Cayman Chemical. Retrieved 15 July 2015.
  2. ↑ WO 2009106982, Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DL, Kortum SW, Rico JG, Tenbrink RE, Wu KK, "Indazole derivatives", published 3 September 2009, assigned to Pfizer Inc
  3. ↑ "Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 16 July 2015.
  4. ↑ Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (December 2020). "in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.